|
FR2338043A1
(fr)
|
1976-01-13 |
1977-08-12 |
Delmar Chem |
Derives de 4-arylpiperidine et procedes de production
|
|
US4132710A
(en)
|
1976-12-20 |
1979-01-02 |
Ayerst, Mckenna And Harrison, Ltd. |
[2]Benzopyrano[3,4-c]pyridines and process therefor
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
IN164232B
(enExample)
|
1986-04-11 |
1989-02-04 |
Hoechst India |
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
JP2691986B2
(ja)
|
1987-08-28 |
1997-12-17 |
チッソ株式会社 |
ピリジン骨格を有する光学活性化合物の製造法
|
|
DE3743824C2
(de)
|
1987-12-23 |
1997-03-06 |
Hoechst Ag |
Verfahren zur enzymatischen Racematspaltung von racemischen Alkoholen mit/in Vinylestern durch Umesterung
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5284856A
(en)
|
1988-10-28 |
1994-02-08 |
Hoechst Aktiengesellschaft |
Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
|
|
DE3836676A1
(de)
|
1988-10-28 |
1990-05-03 |
Hoechst Ag |
Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
|
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
|
EP0479909B1
(en)
|
1989-06-29 |
1996-10-30 |
Medarex, Inc. |
Bispecific reagents for aids therapy
|
|
US5674980A
(en)
|
1989-12-21 |
1997-10-07 |
Biogen Inc |
Fusion protein comprising tat-derived transport moiety
|
|
US5804604A
(en)
|
1989-12-21 |
1998-09-08 |
Biogen, Inc. |
Tat-derived transport polypeptides and fusion proteins
|
|
ES2284161T3
(es)
|
1990-01-12 |
2007-11-01 |
Amgen Fremont Inc. |
Generacion de anticuerpos xenogenicos.
|
|
ATE116100T1
(de)
|
1990-08-09 |
1995-01-15 |
Francaise Coop Pharma |
Stabile natriumhypochloritlösung.
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
AU8507191A
(en)
|
1990-08-29 |
1992-03-30 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
JPH0641075A
(ja)
|
1990-09-01 |
1994-02-15 |
Kazuo Achinami |
新規な１，４−ジヒドロピリジン化合物及びその製造方法
|
|
AU647603B2
(en)
|
1991-04-02 |
1994-03-24 |
Hoechst Aktiengesellschaft |
An immobilized biocatalyst, its preparation and use for ester synthesis in a column reactor
|
|
WO1992020373A1
(en)
|
1991-05-14 |
1992-11-26 |
Repligen Corporation |
Heteroconjugate antibodies for treatment of hiv infection
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
|
WO1993016185A2
(en)
|
1992-02-06 |
1993-08-19 |
Creative Biomolecules, Inc. |
Biosynthetic binding protein for cancer marker
|
|
ES2301158T3
(es)
|
1992-07-24 |
2008-06-16 |
Amgen Fremont Inc. |
Produccion de anticuerpos xenogenicos.
|
|
US6177401B1
(en)
|
1992-11-13 |
2001-01-23 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
|
|
DE69303494T2
(de)
|
1992-11-13 |
1997-01-16 |
Idec Pharma Corp |
Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
|
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
|
GB9422836D0
(en)
|
1994-11-11 |
1995-01-04 |
Wainscoat James |
Monitoring malignant disease
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
|
JP3053222B2
(ja)
|
1995-04-20 |
2000-06-19 |
ファイザー・インコーポレーテッド |
Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
|
|
EP0822830B1
(en)
|
1995-04-27 |
2008-04-02 |
Amgen Fremont Inc. |
Human anti-IL-8 antibodies, derived from immunized xenomice
|
|
WO1996034096A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
DE69637147T2
(de)
|
1995-07-28 |
2008-03-06 |
Marie Curie Cancer Care |
Transportproteine und deren verwendungen
|
|
GB9520822D0
(en)
|
1995-10-11 |
1995-12-13 |
Wellcome Found |
Therapeutically active compounds
|
|
US5733920A
(en)
|
1995-10-31 |
1998-03-31 |
Mitotix, Inc. |
Inhibitors of cyclin dependent kinases
|
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
ATE225343T1
(de)
|
1995-12-20 |
2002-10-15 |
Hoffmann La Roche |
Matrix-metalloprotease inhibitoren
|
|
EP0888458A4
(en)
|
1996-02-20 |
2004-05-06 |
Sloan Kettering Institutefor C |
COMBINATION OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCER
|
|
ES2169355T3
(es)
|
1996-03-05 |
2002-07-01 |
Astrazeneca Ab |
Derivados de 4-anilinoquinazolina.
|
|
US6087366A
(en)
|
1996-03-07 |
2000-07-11 |
The Trustees Of Columbia University In The City Of New York |
Use of flavopiridol or a pharmaceutically acceptable salt thereof for inhibiting cell damage or cell death
|
|
US5849733A
(en)
|
1996-05-10 |
1998-12-15 |
Bristol-Myers Squibb Co. |
2-thio or 2-oxo flavopiridol analogs
|
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
|
EA199900021A1
(ru)
|
1996-07-13 |
1999-08-26 |
Глаксо, Груп Лимитед |
Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
DE69716916T2
(de)
|
1996-07-13 |
2003-07-03 |
Glaxo Group Ltd., Greenford |
Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
|
|
CA2260898C
(en)
|
1996-07-18 |
2002-05-14 |
Pfizer Limited |
Phosphinate based inhibitors of matrix metalloproteases
|
|
PL331895A1
(en)
|
1996-08-23 |
1999-08-16 |
Pfizer |
Arylosulphonylamino derivatives of hydroxamic acid
|
|
US5965703A
(en)
|
1996-09-20 |
1999-10-12 |
Idun Pharmaceuticals |
Human bad polypeptides, encoding nucleic acids and methods of use
|
|
US5908934A
(en)
|
1996-09-26 |
1999-06-01 |
Bristol-Myers Squibb Company |
Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
|
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
|
DE69730151T2
(de)
|
1997-01-06 |
2005-08-04 |
Pfizer Inc. |
Cyclische sulfonderivate
|
|
AU721748B2
(en)
|
1997-02-03 |
2000-07-13 |
Pfizer Products Inc. |
Arylsulfonylamino hydroxamic acid derivatives
|
|
KR20000070751A
(ko)
|
1997-02-05 |
2000-11-25 |
로즈 암스트롱, 크리스틴 에이. 트러트웨인 |
세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
|
|
CA2279863A1
(en)
|
1997-02-07 |
1998-08-13 |
Pfizer Inc. |
N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
|
|
WO1998034918A1
(en)
|
1997-02-11 |
1998-08-13 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives
|
|
GB9704444D0
(en)
|
1997-03-04 |
1997-04-23 |
Isis Innovation |
Non-invasive prenatal diagnosis
|
|
CA2289102A1
(en)
|
1997-05-07 |
1998-11-12 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
|
JP2002501532A
(ja)
|
1997-05-30 |
2002-01-15 |
メルク エンド カンパニー インコーポレーテッド |
新規血管形成阻害薬
|
|
ID23668A
(id)
|
1997-08-08 |
2000-05-11 |
Pfizer Prod Inc |
Turunan asam ariloksiarilsulfonilamino hidroksamat
|
|
ATE368665T1
(de)
|
1997-08-22 |
2007-08-15 |
Astrazeneca Ab |
Oxindolylchinazolinderivate als angiogenesehemmer
|
|
CA2304124A1
(en)
|
1997-09-17 |
1999-03-25 |
The Walter And Eliza Hall Institute Of Medical Research |
Bci-2-like protein bim and methods of use thereof
|
|
AU9402898A
(en)
|
1997-09-26 |
1999-04-23 |
Washington University |
Cell death agonists
|
|
JP2001518470A
(ja)
|
1997-09-26 |
2001-10-16 |
メルク エンド カムパニー インコーポレーテッド |
新規な血管形成阻害剤
|
|
WO1999024440A1
(en)
|
1997-11-11 |
1999-05-20 |
Pfizer Products Inc. |
Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
|
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
|
DE19802449A1
(de)
|
1998-01-23 |
1999-07-29 |
Hoechst Marion Roussel De Gmbh |
Verfahren zur Herstellung von (-)cis-3-Hydroxy-1-methyl-4-(2,4,6-trimethoxypyhenyl)-piperidin
|
|
US6437136B2
(en)
|
1998-01-23 |
2002-08-20 |
Aventis Pharma Deutschland Gmbh |
Process for the preparation of (−)cis-3-hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)piperidine
|
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
|
DE19809649A1
(de)
|
1998-03-06 |
1999-09-09 |
Hoechst Marion Roussel De Gmbh |
Verfahren zur enzymatischen Enantiomeren-Trennung von 3(R)- und 3(S)-Hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)-1,2,3,6-tetrahydro-pyridin bzw. der Carbonsäureester
|
|
JP4462654B2
(ja)
|
1998-03-26 |
2010-05-12 |
ソニー株式会社 |
映像素材選択装置及び映像素材選択方法
|
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
|
US20020029391A1
(en)
|
1998-04-15 |
2002-03-07 |
Claude Geoffrey Davis |
Epitope-driven human antibody production and gene expression profiling
|
|
IL139934A0
(en)
|
1998-05-29 |
2002-02-10 |
Sugen Inc |
Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same
|
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
|
FR2780056B1
(fr)
|
1998-06-18 |
2000-08-04 |
Hoechst Marion Roussel Inc |
Nouveau procede de preparation de derives de la 4-phenyl-1-2 3,6-tetrahydropyridine et les produits imtermediaires mis en oeuvre
|
|
PT1100589E
(pt)
|
1998-07-30 |
2005-05-31 |
Sigma Tau Ind Farmaceuti |
Utilizacao de propionil-l-carnitina e acetil-l-carnitina na preparacao de medicamentos com actividade anticancerigena
|
|
US6268499B1
(en)
|
1998-08-10 |
2001-07-31 |
Hoffman-La Roche Inc. |
Process and intermediates for preparation of substituted piperidine-epoxides
|
|
WO2000012071A2
(de)
|
1998-08-29 |
2000-03-09 |
Miklos Ghyczy |
Pharmazeutisches und/oder diätetisches produkt
|
|
DK1004578T3
(da)
|
1998-11-05 |
2004-06-28 |
Pfizer Prod Inc |
5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
|
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
|
US6399633B1
(en)
|
1999-02-01 |
2002-06-04 |
Aventis Pharmaceuticals Inc. |
Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
|
|
EP1210098A1
(en)
|
1999-04-07 |
2002-06-05 |
Thomas Jefferson University |
Enhancement of peptide cellular uptake
|
|
US6511993B1
(en)
|
1999-06-03 |
2003-01-28 |
Kevin Neil Dack |
Metalloprotease inhibitors
|
|
WO2001012661A2
(en)
|
1999-08-16 |
2001-02-22 |
The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services, The National Institutes Of Health |
RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS
|
|
US6576647B2
(en)
|
2000-01-18 |
2003-06-10 |
Aventis Pharmaceuticals Inc. |
Pseudopolymorph of (—)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy -1-methyl)piperidinyl]-4H-1-benzopyran-4-one
|
|
US6821990B2
(en)
|
2000-01-18 |
2004-11-23 |
Aventis Pharma Deutschland Gmbh |
Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5, 7-dihydroxy-8 [4R-(3S-hydroxy-1-M ethyl) piperidinyl]-4H-1-benzopyran-4-one
|
|
AR034118A1
(es)
|
2000-02-15 |
2004-02-04 |
Sugen Inc |
Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis
|
|
WO2001080896A2
(en)
|
2000-04-21 |
2001-11-01 |
Arch Development Corporation |
Flavopiridol drug combinations and methods with reduced side effects
|
|
WO2002020568A2
(en)
|
2000-09-06 |
2002-03-14 |
Abbott Laboratories |
Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins
|
|
WO2002046182A1
(en)
|
2000-12-08 |
2002-06-13 |
Bristol-Myers Squibb Pharma Company |
Semicarbazides and their uses as cyclin dependent kinase inhibitors
|
|
AU2002258399A1
(en)
|
2001-02-16 |
2002-09-19 |
Medical College Of Georgia Research Institute, Inc. |
Use of trail and antiprogestins for treating cancer
|
|
US8552054B2
(en)
|
2001-03-23 |
2013-10-08 |
Luitpold Pharmaceuticals, Inc. |
Fatty amine drug conjugates
|
|
JP4634694B2
(ja)
|
2001-03-23 |
2011-02-16 |
ルイトポルド・ファーマシューティカルズ・インコーポレーテッド |
脂肪アルコール薬物複合体
|
|
KR20030026069A
(ko)
|
2001-09-24 |
2003-03-31 |
주식회사 엘지생명과학 |
티엔에프계 단백질과 플라보피리돌의 조합에 의한 암세포특이적인 세포사멸 유도용 조성물
|
|
US20030073661A1
(en)
|
2001-09-24 |
2003-04-17 |
Shigemi Matsuyama |
Method of modulating or examining Ku70 levels in cells
|
|
WO2003040168A2
(en)
|
2001-11-06 |
2003-05-15 |
Enanta Pharmaceuticals, Inc. |
Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
|
|
CA2471719A1
(en)
|
2001-12-31 |
2003-07-17 |
Dana-Farber Cancer Institute, Inc. |
Method of treating apoptosis and compositions thereof
|
|
CA2478047C
(en)
|
2002-03-01 |
2014-01-21 |
Immunomedics, Inc. |
Rs7 antibodies
|
|
US20040106647A1
(en)
|
2002-06-28 |
2004-06-03 |
Schneider Michael D. |
Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
|
|
AU2003267124A1
(en)
|
2002-09-09 |
2004-03-29 |
Dana-Farber Cancer Institute, Inc. |
Bh3 peptides and method of use thereof
|
|
WO2004058804A1
(en)
|
2002-12-24 |
2004-07-15 |
Walter And Eliza Hall Institute Of Medical Research |
Peptides and therapeutic uses thereof
|
|
JP2006524710A
(ja)
|
2003-04-25 |
2006-11-02 |
ギリアード サイエンシーズ， インコーポレイテッド |
キナーゼインヒビターホスホネート抱合体
|
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
|
GB0315259D0
(en)
|
2003-06-30 |
2003-08-06 |
Cyclacel Ltd |
Use
|
|
NZ544797A
(en)
|
2003-07-18 |
2011-04-29 |
Amgen Fremont Inc |
Specific antibodies that bind HGF and neutralise binding of HGF to met
|
|
CN1302004C
(zh)
|
2003-08-22 |
2007-02-28 |
浙江海正药业股份有限公司 |
一种阿糖胞苷的制备方法
|
|
WO2005044839A2
(en)
|
2003-11-05 |
2005-05-19 |
Dana-Farber Cancer Institute, Inc. |
Stabilized alpha helical peptides and uses thereof
|
|
WO2006069186A2
(en)
|
2004-12-22 |
2006-06-29 |
The Ohio State Research Foundation |
Small molecule bcl-xl/bcl-2 binding inhibitors
|
|
WO2006101846A1
(en)
|
2005-03-16 |
2006-09-28 |
Aventis Pharmaceuticals Inc. |
Dosing regimen of flavopiridol for treating cancer in particular cll
|
|
WO2006099667A1
(en)
|
2005-03-21 |
2006-09-28 |
The Walter And Eliza Hall Institute Of Medical Research |
Prophylactic and therapeutic agents and uses therefor
|
|
US7750000B2
(en)
|
2005-09-02 |
2010-07-06 |
Bayer Schering Pharma Ag |
Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
|
|
EP2008106A2
(en)
|
2006-03-31 |
2008-12-31 |
Dana-Farber Cancer Institute |
Methods of determining cellular chemosensitivity
|
|
JP2009536186A
(ja)
*
|
2006-05-08 |
2009-10-08 |
アステックス・セラピューティクス・リミテッド |
癌処置のためのジアゾール誘導体の医薬組合せ
|
|
WO2008021484A2
(en)
|
2006-08-16 |
2008-02-21 |
Eutropics Pharmaceuticals |
Assay system to identify therapeutic agents
|
|
ES2383370T3
(es)
*
|
2006-10-19 |
2012-06-20 |
Signal Pharmaceuticals Llc |
Compuestos de heteroarilo, sus composiciones y uso de los mismos como inhibidores de proteína quinasa
|
|
AU2008221278A1
(en)
|
2007-03-01 |
2008-09-04 |
Supergen, Inc. |
Pyrimidine-2,4-diamine derivatives and their use as JAK2 kinase inhibitors
|
|
GB0706633D0
(en)
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
Combination
|
|
RU2438664C2
(ru)
|
2007-05-15 |
2012-01-10 |
Пирамал Лайф Сайнсиз Лимитед |
Синергическая фармацевтическая комбинация для лечения рака
|
|
ATE538652T1
(de)
|
2007-05-15 |
2012-01-15 |
Piramal Life Sciences Ltd |
Synergistische pharmazeutische kombination für die behandlung von krebs
|
|
WO2009014642A1
(en)
|
2007-07-19 |
2009-01-29 |
Amgen Inc. |
Combination of a de novo purine biosynthesis inhibitor and a cyclin dependent kinase inhibitor for the treatment of cancer
|
|
WO2009042237A2
(en)
|
2007-09-26 |
2009-04-02 |
Dana Farber Cancer Institute |
Methods and compositions for modulating bcl-2 family polypeptides
|
|
EP2249831A2
(en)
|
2007-12-10 |
2010-11-17 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
|
|
TWI378781B
(en)
|
2008-03-12 |
2012-12-11 |
Jung Tang Huang |
A belt integrated with stress sensing and output reaction
|
|
WO2009137664A1
(en)
|
2008-05-07 |
2009-11-12 |
Eutropics Pharmaceuticals, Inc. |
Antibodies specific to heterodimers of bcl-2 family and uses thereof
|
|
KR101667641B1
(ko)
*
|
2008-06-09 |
2016-10-20 |
싸이클라셀 리미티드 |
데시타빈 및 프로카인과 같은 ｄｎａ 메틸전이효소 저해제와 사팍시타빈 또는 ｃｎｄａｃ의 조합
|
|
TWI453207B
(zh)
*
|
2008-09-08 |
2014-09-21 |
Signal Pharm Llc |
胺基三唑并吡啶，其組合物及使用其之治療方法
|
|
US9045800B2
(en)
|
2009-02-11 |
2015-06-02 |
Abbvie Inc. |
Methods and compositions for identifying, classifying and monitoring subject having Bcl-2 family inhibitor-resistant tumors and cancers
|
|
EP3243527B1
(en)
|
2009-02-13 |
2019-06-05 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
|
WO2010147961A1
(en)
|
2009-06-15 |
2010-12-23 |
Precision Therapeutics, Inc. |
Methods and markers for predicting responses to chemotherapy
|
|
WO2011088137A2
(en)
|
2010-01-12 |
2011-07-21 |
H. Lee Moffitt Cancer Center & Research Institute |
Bad pathway gene signature
|
|
US8372819B2
(en)
|
2010-04-11 |
2013-02-12 |
Salk Institute For Biological Studies |
Methods and compositions for targeting skip
|
|
MX373121B
(es)
|
2010-05-14 |
2020-04-30 |
Dana Farber Cancer Inst Inc |
Composiciones y metodos para el tratamiento de leucemia.
|
|
SG180031A1
(en)
*
|
2010-10-15 |
2012-05-30 |
Agency Science Tech & Res |
Combination treatment of cancer
|
|
EP2655334B1
(en)
|
2010-12-22 |
2018-10-03 |
Eutropics Pharmaceuticals, Inc. |
Compositions and methods useful for treating diseases
|
|
WO2012122370A2
(en)
|
2011-03-08 |
2012-09-13 |
Eutropics Pharmaceuticals, Inc. |
Compositions and methods useful for treating diseases
|
|
CA2844407A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
|
|
EP2561867A1
(en)
|
2011-08-22 |
2013-02-27 |
Lead Discovery Center GmbH |
CDK9 inhibitors in the treatment of midline carcinoma
|
|
US9012215B2
(en)
|
2011-09-22 |
2015-04-21 |
The Johns Hopkins University |
Methods for identifying leukemia stem cells and distinguishing them from normal hematopietic stem cells in patients with acute myeloid leukemia: uses in diagnosis, treatment, and research
|
|
US20130122492A1
(en)
|
2011-11-14 |
2013-05-16 |
Kellbenx Inc. |
Detection, isolation and analysis of rare cells in biological fluids
|
|
WO2013082660A1
(en)
|
2011-12-09 |
2013-06-13 |
Alfred Health |
Prediction method
|
|
WO2013138702A2
(en)
|
2012-03-15 |
2013-09-19 |
Bristol-Myers Squibb Company |
Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
|
|
US9926306B2
(en)
|
2012-03-20 |
2018-03-27 |
Dana-Farber Cancer Institute, Inc. |
Inhibition of MCL-1 and/or BFL-1/A1
|
|
JP2015519565A
(ja)
|
2012-05-10 |
2015-07-09 |
ユートロピクス ファーマシューティカルズ， インコーポレイテッド |
がんに対する補助的機能診断テスト
|
|
WO2013182519A1
(en)
|
2012-06-04 |
2013-12-12 |
Universitaet Basel |
Combination of lysosomotropic or autophagy modulating agents and a gsk-3 inhibitor for treatment of cancer
|
|
WO2013188355A1
(en)
|
2012-06-12 |
2013-12-19 |
Merck Sharp & Dohme Corp. |
Cdk inhibitor for treating refractory chronic lymphocytic leukemia
|
|
US20150322479A1
(en)
|
2012-06-20 |
2015-11-12 |
Cytospan Technologies Corporation |
Apparatus and method for quantification of replicative lifespan and observation of senescene
|
|
IN2014DN11205A
(enExample)
|
2012-06-20 |
2015-10-02 |
Eutropics Pharmaceuticals Inc |
|
|
WO2014047342A1
(en)
|
2012-09-19 |
2014-03-27 |
Dana-Farber Cancer Institute, Inc. |
Dynamic bh3 profiling
|
|
US9241941B2
(en)
|
2012-09-20 |
2016-01-26 |
Memorial Sloan-Kettering Cancer Center |
Methods for treatment of lymphomas with mutations in cell cycle genes
|
|
CN104812756A
(zh)
|
2012-09-26 |
2015-07-29 |
曼凯德公司 |
多激酶通路抑制剂
|
|
JP2015533832A
(ja)
|
2012-10-09 |
2015-11-26 |
アイジェニカ バイオセラピューティクス インコーポレイテッド |
抗Ｃ１６ｏｒｆ５４抗体およびその使用方法
|
|
CN104981242A
(zh)
|
2012-10-23 |
2015-10-14 |
帝人制药株式会社 |
肿瘤溶解综合征的治疗药和预防药
|
|
WO2014066848A1
(en)
|
2012-10-25 |
2014-05-01 |
Whitehead Institute For Biomedical Research |
Super-enhancers and methods of use thereof
|
|
DK2945628T3
(da)
|
2013-01-15 |
2020-05-04 |
Aragon Pharmaceuticals Inc |
Androgen receptormodulator i kombination med abirateronacetat og prednison til behandling af prostatacancer
|
|
US20160178612A1
(en)
|
2013-07-18 |
2016-06-23 |
Eutropics Pharmaceuticals, Inc. |
Differential bh3 mitochondrial profiling
|
|
US10732182B2
(en)
|
2013-08-01 |
2020-08-04 |
Eutropics Pharmaceuticals, Inc. |
Method for predicting cancer sensitivity
|
|
EP3047276B1
(en)
|
2013-09-19 |
2023-06-14 |
Dana-Farber Cancer Institute, Inc. |
Methods of bh3 profiling
|
|
CA2920192A1
(en)
|
2013-09-27 |
2015-04-02 |
Immunomedics, Inc. |
Anti-trop-2 antibody-drug conjugates and uses thereof
|
|
US10640803B2
(en)
|
2013-10-30 |
2020-05-05 |
Eutropics Pharmaceuticals, Inc. |
Methods for determining chemosensitivity and chemotoxicity
|
|
EP3066101B1
(en)
|
2013-11-08 |
2020-07-29 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
|
|
US9925192B2
(en)
|
2014-02-28 |
2018-03-27 |
Merck Sharp & Dohme Corp. |
Method for treating cancer
|
|
WO2015161247A1
(en)
*
|
2014-04-17 |
2015-10-22 |
Igenica Biotherapeutics, Inc. |
Humanized anti-c16orf54 antibodies and methods of use thereof
|
|
ES2891332T3
(es)
|
2014-09-17 |
2022-01-27 |
Novartis Ag |
Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
|
|
US10300073B2
(en)
|
2014-10-14 |
2019-05-28 |
The Regents Of The University Of California |
Use of CDK9 and BRD4 inhibitors to inhibit inflammation
|
|
WO2016073913A1
(en)
|
2014-11-07 |
2016-05-12 |
Tolero Pharmaceuticals, Inc. |
Methods to target transcriptional control at super-enhancer regions
|
|
EP3245301B1
(en)
|
2015-01-12 |
2020-11-11 |
Eutropics Pharmaceuticals, Inc. |
Context dependent diagnostics test for guiding cancer treatment
|
|
WO2016133910A1
(en)
|
2015-02-17 |
2016-08-25 |
Cantex Pharmaceuticals, Inc. |
Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
|
|
US11142554B2
(en)
|
2015-03-18 |
2021-10-12 |
Massachusetts Institute Of Technology |
Selective Mcl-1 binding peptides
|
|
US20180100859A1
(en)
|
2015-03-24 |
2018-04-12 |
Eutropics Pharmaceuticals, Inc. |
Surrogate functional biomarker for solid tumor cancer
|
|
WO2016161248A1
(en)
|
2015-04-02 |
2016-10-06 |
Tolero Pharmaceuticals, Inc. |
Targeting pim kinases in combination with btk inhibition
|
|
EP3611506B1
(en)
|
2015-04-20 |
2021-11-17 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
|
WO2016176299A1
(en)
|
2015-04-27 |
2016-11-03 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for assessing toxicity using dynamic bh3 profiling
|
|
PL3298021T3
(pl)
|
2015-05-18 |
2019-11-29 |
Tolero Pharmaceuticals Inc |
Proleki alvocidibu o zwiększonej biodostępności
|
|
WO2017024073A1
(en)
*
|
2015-08-03 |
2017-02-09 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
|
WO2017075349A2
(en)
|
2015-10-30 |
2017-05-04 |
Massachusetts Institute Of Technology |
Selective mcl-1 binding peptides
|
|
US9782232B1
(en)
|
2016-04-25 |
2017-10-10 |
Novartis Ag |
Automated intraocular pressure tamponade
|
|
CN105919955A
(zh)
|
2016-06-13 |
2016-09-07 |
佛山市腾瑞医药科技有限公司 |
一种鲁索利替尼制剂及其应用
|
|
SG11201900344YA
(en)
|
2016-07-15 |
2019-02-27 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
KR20190099260A
(ko)
|
2016-12-19 |
2019-08-26 |
톨레로 파마수티컬스, 인크. |
프로파일링 펩티드 및 감도 프로파일링을 위한 방법
|
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
|
WO2019200243A1
(en)
|
2018-04-13 |
2019-10-17 |
Tolero Pharmaceuticals, Inc. |
Cyclin-dependent kinase inhibitors in combination with anthracyclines for treatment of cancer
|
|
US20210277037A1
(en)
|
2018-06-21 |
2021-09-09 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Deuterated alvocidib and alvocidib prodrugs
|